An A2AR antagonist (Ciforadenant, CPI-441) was tested in 502 patients with solid cancers including melanoma as a monotherapy or in combination with atezolizumab in a phase-I study (NCT02655822). This evidence concerns the gene ADORA2A and melanoma.